Using Science, Diet and Technology to Revolutionize the GI Market
Biomerica has filed over 100 international and PCT (Patent Cooperation Treaty) patents, and has 12 provisional and non-provisional patents currently filed with the USPTO (United States Patent and Trademark Office).
Our most important family of patent applications pertains to our inFoods® technology platform, which is a revolutionary and disruptive new method of possibly diagnosing and treating symptoms of many different diseases.
inFoods® is the world´s first test measuring food sensitivities based on scientific evidence and optimized for each disease.
The inFoods® Family of Patents
Biomerica has filed many patent applications with the USPTO and with other such similar agencies in other countries outside of the United States pertaining to this inFoods® technology. These patent applications include claims that address the diagnosis and treatment of several disease states including:
- Irritable Bowel Syndrome (IBS),
- Inflammatory Bowel Disease (IBD)
- Crohn’s disease,
- Ulcerative colitis,
- Functional dyspepsia,
- Gastroesophageal reflux disease,
- Osteoarthritis,
- Psoriasis,
- Migraine Headaches,
- Depression
These applications include the use of this technology in both humans and animals. The first patents filed by Biomerica pertained to IBS. Several of the patents pertaining to the inFoods® IBS technology have been issued and many more are in active review and prosecution.
Granted and Allowed Patents
The Australian Patent Office issued a notice of allowance for an InFoods® IBS patent (2020233774)
The Korean Patent Office issued a third InFoods® IBS patent (10-2021-7006347)
The Canadian Patent Office issued a notice of allowance for a second InFoods® IBS patent (2967817).
The Japanese Patent Office issued our fourth InFoods® IBS patent (2019-500576).
The Australian Patent Office issued a notice of allowance for a second InFoods® IBS patent (2017283493).
Recent Patent
Notifications of Patent Grant by the China National Intellectual Property Administration (CNIPA) on May 17, 2023.
What if the results from a simple blood test could decipher which foods trigger IBS symptoms?